Product Name :
Senexin A
Description:
Senexin A is a CDK8 inhibitor with an IC50 of 280 nM.
CAS:
1366002-50-7
Molecular Weight:
274.32
Formula:
C17H14N4
Chemical Name:
4-[(2-phenylethyl)amino]quinazoline-6-carbonitrile
Smiles :
N#CC1=CC2C(NCCC3C=CC=CC=3)=NC=NC=2C=C1
InChiKey:
XBJCNHGQFJFCOY-UHFFFAOYSA-N
InChi :
InChI=1S/C17H14N4/c18-11-14-6-7-16-15(10-14)17(21-12-20-16)19-9-8-13-4-2-1-3-5-13/h1-7,10,12H,8-9H2,(H,19,20,21)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Senexin A is a CDK8 inhibitor with an IC50 of 280 nM.Certolizumab pegol Apoptosis |Product information|CAS Number: 1366002-50-7|Molecular Weight: 274.6PPD-Q Immunology/Inflammation 32|Formula: C17H14N4|Chemical Name: 4-[(2-phenylethyl)amino]quinazoline-6-carbonitrile|Smiles: N#CC1=CC2C(NCCC3C=CC=CC=3)=NC=NC=2C=C1|InChiKey: XBJCNHGQFJFCOY-UHFFFAOYSA-N|InChi: InChI=1S/C17H14N4/c18-11-14-6-7-16-15(10-14)17(21-12-20-16)19-9-8-13-4-2-1-3-5-13/h1-7,10,12H,8-9H2,(H,19,20,21)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (364.54 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:32448000 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Senexin A inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 μM and 0.31 μM, respectively and CDK8 kinase activity with IC50 of 0.28 μM. Senexin A inhibits β-catenin–dependent transcription in HCT116 colon carcinoma cells. The induction of transcription factor EGR1 upon serum starvation, followed by readdition of serum, is strongly inhibited by Senexin A in HT1080 cells. Senexin A inhibits only p21-induced transcription but not other biological effects of p21. Senexin A also decreases the expression of many secreted tumor-promoting factors in doxorubicin-treated wild-type HCT116 cells.|In Vivo:|Five daily treatment of Senexin A fully reverses tumor-promoting effect of chemotherapy. Senexin A shows no detectable toxicity and no significant effects on body weight, organ weights, or blood cell counts in C57BL/6 mice during the treatment. This effect of doxorubicin treatment is completely abolished, however, when doxorubicin injection is followed by administration of Senexin A. Senexin A treatment strongly improves the response of A549/MEF tumors to doxorubicin.|Products are for research use only. Not for human use.|
